This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

Moderna Inc MRNA shares are rising in Tuesday’s after-hours session after the company announced it reached a settlement agreement with Arbutus Biopharma and Genevant Sciences. Moderna shares are ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.

Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s ...

Moderna (MRNA) stock rises as a $950M payment to resolve a patent dispute with Arbutus (ABUS) and Roivant (ROIV) lifts a key legal overhang. Read more here.

Moderna (MRNA) stock jumped 8.7% after announcing a $950M patent settlement with Arbutus and Genevant, the largest pharma patent deal ever recorded.

Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company’s value has increased by approximately $1.2 billion over ...

Shares of Moderna MRNA rose about 4% on Friday after the company announced that the EMA’s Committee for Medicinal Products ...

BioNTech stock crumbled Tuesday after the cofounders of the German biotech announced their plan to step down.

Uğur Şahin, M.D., who is currently the CEO of BioNTech, and his wife Özlem Türeci, M.D., who is chief medical officer, founded mRNA-focused BioNTech in 2008. The company rose to prominence and ...